Published in J Immunol on October 01, 2007
Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology (2008) 0.98
Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol (2015) 0.93
Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron (2012) 0.87
Natural killer cells in patients with severe chronic fatigue syndrome. Auto Immun Highlights (2013) 0.86
Comparative expression profiling of distinct T cell subsets undergoing oxidative stress. PLoS One (2012) 0.85
Reduction of the CD16(-)CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer. PLoS One (2013) 0.82
Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts. Immunology (2014) 0.80
Role of the ERK pathway for oxidant-induced parthanatos in human lymphocytes. PLoS One (2014) 0.80
Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment. Transfus Med Hemother (2016) 0.78
Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity. J Immunol (2015) 0.77
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. Oncotarget (2016) 0.77
Metabolism pathways in chronic lymphocytic leukemia. Leuk Lymphoma (2015) 0.75
Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells. Front Immunol (2017) 0.75
Bystander cells enhance NK cytotoxic efficiency by reducing search time. Sci Rep (2017) 0.75
Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation. Oncotarget (2016) 0.75
Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood (2010) 3.58
Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol (2007) 3.33
Heat-shock proteins as activators of the innate immune system. Trends Immunol (2002) 2.96
Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med (2010) 2.89
Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood (2009) 2.88
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res (2010) 2.74
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Circulating heat shock protein and heat shock protein antibody levels in established hypertension. J Hypertens (2002) 2.05
NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood (2013) 2.04
Regulatory T cells in cancer. Adv Cancer Res (2010) 2.02
Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood (2008) 1.96
KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood (2009) 1.92
Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant (2011) 1.90
CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol (2011) 1.81
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. 1986. J Immunol (2005) 1.64
DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res (2007) 1.45
Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity? J Immunother (2011) 1.44
FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol (2006) 1.43
Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol (2009) 1.38
Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci (2009) 1.37
Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother (2011) 1.36
Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). J Hum Genet (2011) 1.35
Distinct infiltration of neutrophils in lesion shoulders in ApoE-/- mice. Am J Pathol (2010) 1.35
On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol (2012) 1.35
NFAM1, an immunoreceptor tyrosine-based activation motif-bearing molecule that regulates B cell development and signaling. Proc Natl Acad Sci U S A (2004) 1.25
IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest (2002) 1.24
The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood (2011) 1.24
Identification of novel molecular targets regulated by tumor suppressive miR-1/miR-133a in maxillary sinus squamous cell carcinoma. Int J Oncol (2011) 1.24
A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci U S A (2006) 1.22
Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res (2002) 1.18
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A (2008) 1.18
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer (2004) 1.17
Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res (2013) 1.17
Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol (2003) 1.17
Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. J Immunol (2008) 1.17
T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol (2009) 1.15
Classification of human natural killer cells based on migration behavior and cytotoxic response. Blood (2013) 1.15
Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood (2010) 1.14
NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood (2010) 1.14
Is survivin the potential Achilles' heel of cancer? Adv Cancer Res (2011) 1.12
HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol (2002) 1.08
Application of nine-color flow cytometry for detailed studies of the phenotypic complexity and functional heterogeneity of human lymphocyte subsets. J Immunol Methods (2007) 1.07
Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L). Cancer Immunol Immunother (2002) 1.05
NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur J Immunol (2011) 1.05
Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation (2004) 1.05
Detection of human perforin by ELISpot and ELISA: ex vivo identification of virus-specific cells. J Immunol Methods (2005) 1.04
Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res (2004) 1.04
CD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells. Blood (2012) 1.04
T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer (2010) 1.03
Functional gap junctions facilitate melanoma antigen transfer and cross-presentation between human dendritic cells. J Immunol (2007) 1.01
Influence of KIR gene copy number on natural killer cell education. Blood (2013) 1.00
HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. J Immunol (2012) 1.00
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother (2008) 1.00
Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress. J Immunol (2008) 0.98
Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer (2010) 0.98
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res (2013) 0.97
Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Res (2006) 0.97
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. Int J Cancer (2011) 0.97
Immunization with heat shock protein 70 from methylcholanthrene-induced sarcomas induces tumor protection correlating with in vitro T cell responses. Cancer Immunol Immunother (2002) 0.97
A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res (2005) 0.97
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med (2010) 0.97
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol (2013) 0.96
Differential effects of reduced glycoprotein VI levels on activation of murine platelets by glycoprotein VI ligands. Biochem J (2002) 0.96
Expression and prognostic significance of iNOS in uveal melanoma. Int J Cancer (2010) 0.96
Elevated numbers of Fc gamma RIIIA+ (CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infection. J Immunol (2008) 0.96
Interactions of NK cell receptor KIR3DL1*004 with chaperones and conformation-specific antibody reveal a functional folded state as well as predominant intracellular retention. J Immunol (2010) 0.95
Tracing dynamic expansion of human NK-cell subsets by high-resolution analysis of KIR repertoires and cellular differentiation. Eur J Immunol (2014) 0.95
Characterization of natural killer cell phenotype and function during recurrent human HSV-2 infection. PLoS One (2011) 0.94
Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother (2005) 0.94
Preferential cell death of CD8+ effector memory (CCR7-CD45RA-) T cells by hydrogen peroxide-induced oxidative stress. J Immunol (2005) 0.94
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol Immunother (2008) 0.94
A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol (2012) 0.94
Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation. Stem Cells (2013) 0.93